Fulcrum Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2024, reporting a cash position of $241 million, providing a runway into at least 2027.
FULCRUM THERAPEUTICS ($FULC) posted quarterly earnings results on Tuesday, February 25th. The company reported earnings of -$0.31 per share, beating estimates of -$0. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback